Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Auro Vaccines
Deal Size : Undisclosed
Deal Type : Termination
Auro Vaccines Terminates License Agreement with Hilleman Laboratories Singapore
Details : Auro terminated the license agreement with Hilleman Labs to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 06, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Auro Vaccines
Deal Size : Undisclosed
Deal Type : Termination